Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000199306 | SCV000253649 | likely benign | Multiple endocrine neoplasia, type 1 | 2025-01-14 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000400551 | SCV000373089 | uncertain significance | Multiple endocrine neoplasia | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000311483 | SCV000373090 | uncertain significance | Hyperparathyroidism | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000566719 | SCV000673641 | likely benign | Hereditary cancer-predisposing syndrome | 2016-07-01 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV003917813 | SCV004732867 | likely benign | MEN1-related disorder | 2020-07-13 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |